Freshpet heads into the week of May 11 carrying two conflicting signals: a CEO who sold over $2.3 million of stock at prices well above where the shares now trade, and a short base that jumped nearly 20% in a single week to its highest level in six months.
Short interest is the primary story here. Bears have materially rebuilt their position in the wake of Freshpet's Q1 earnings on May 6, which sent the stock down 7% on the day and nearly 20% over the following five sessions. Short interest as a percentage of free float climbed from roughly 12.9% before the print to 15.3% by May 14 — that's the sharpest weekly jump since early April, taking SI to its highest reading this year. With the stock now down 29% over the past month and trading at $49.35, shorts have the wind at their backs. Borrow conditions remain notably loose: availability is wide, cost to borrow has actually eased to 0.41%, down 17% week-on-week. That low friction means new short positions face no meaningful squeeze pressure — the lending market is not putting any floor under this stock.
Options traders are less aggressive than the short book implies. The put/call ratio dipped to 0.69 on May 15, slightly below its 20-day average of 0.73. That's a mild call-skew, not the defensive pile-on you might expect given the price action. The z-score of -0.78 sits comfortably within one standard deviation of normal. Whatever the options market is pricing, it isn't a panic — positioning there looks relaxed, even as shorts push higher.
The Street's reaction to the earnings miss was swift but measured. JP Morgan's upgrade from Neutral to Overweight — with a $68 target — was the lone constructive move after the print. Wells Fargo maintained Overweight but trimmed its target to $75. Most analysts cut targets earlier in April; Deutsche Bank, B of A, and Jefferies all pulled numbers down through mid-month. The consensus stays at Buy, with eleven of the eleven analysts tracked at a positive rating — but those targets, ranging from $62 to $101, sit a wide distance above the current price. The bull case centres on cost reduction, improved pricing discipline, and category growth in premium pet food. Bears point to rich production costs, an expensive price point that limits the addressable market, and a pattern of execution risk at the earnings line.
Valuation has compressed sharply. The trailing P/E has fallen by more than 15 turns over the past month to around 29x, and the price-to-book has contracted by roughly 0.7 turns to 1.88x. Neither multiple signals obvious distress at current levels, but the contraction reflects just how quickly the narrative has shifted. Factor scores add nuance: EPS surprise ranks in the 98th percentile and EPS momentum over both 30 and 90 days scores in the top decile — meaning estimate-revision trends have been strongly positive even as the stock has sold off. That divergence between fundamental momentum and price action is the central puzzle for bulls.
The insider activity sharpens the caution. On May 11, CEO William Cyr sold just over 46,000 shares across multiple transactions totalling approximately $2.3 million. The sales were executed in the $50–$53 range — above where the stock closed by week's end. On May 8, Chairman Walter George moved the other way, buying 2,000 shares at $54.67 for roughly $109,000. The net 90-day insider position is a positive 54,302 shares — but the scale of the CEO's week-alone selling stands out given the timing, just days after the earnings drop.
The next earnings date is June 10. That gives shorts, bulls, and insiders alike roughly three weeks to resolve a positioning picture that is, for now, decidedly unsettled.
See the live data behind this article on ORTEX.
Open FRPT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
